The utility of insulin glargine in the treatment of diabetes mellitus.

Simple item page
dc.contributor.authorStroup, Jeffrey ++
dc.contributor.authorKane, Michael P
dc.contributor.authorBusch, Robert S
dc.contributor.authorBakst, Gary
dc.contributor.authorHamilton, Robert A
dc.date.accessioned2023-11-21T20:17:15Z
dc.date.available2023-11-21T20:17:15Z
dc.date.issued2004-06
dc.descriptionClick on the Resource Link to access the article (may not be free).
dc.description.abstractStudy objectives: To compare hemoglobin A1c (A1C) values at baseline with those after 1 year of insulin glargine therapy and, secondarily, to compare insulin dosage and patients' body weight at baseline and at 1 year. Design: Retrospective study. Setting: Private endocrinology practice. Patients: One hundred ninety-seven patients with diabetes mellitus who were first prescribed insulin glargine from May 2001-April 2002 and were evaluable after 1 year of therapy Intervention: Patients received insulin glargine instead of NPH insulin or in addition to their oral drug therapy Measurements and main results: Patients with diabetes type 1 (receiving insulin therapy) or type 2 (receiving oral drug therapy only, a combination of oral drug therapy and insulin, or insulin only) who had been treated with insulin glargine for 1 year were evaluated. Overall, A1C values decreased significantly (p<0.001) by 0.53 +/- 1.4% from a baseline mean of 8.1 +/- 1.7%. In 129 patients with type 2 diabetes previously treated with NPH insulin, A1C decreased significantly (p<0.001) 0.57 +/- 1.5% from baseline. The A1C decreased by 0.71 +/- 1.3% (p=0.0043) from baseline in 33 patients with type 2 diabetes who previously received oral agents only Thirty-five patients with type 1 diabetes demonstrated no significant change in A1C (-0.22 +/- 1.0%, p=0.217) from baseline. In patients receiving insulin at baseline, the number of daily injections increased significantly (p<0.0001) from a median of two at baseline to three at 1 year. Overall, no significant change was noted in total daily insulin requirement or in body weight in any of the patient groups over the 1-year period. Conclusion: Compared with baseline, insulin glargine therapy at 1 year was associated with an overall significant reduction in A1C of 0.53 +/- 1.4%.
dc.description.urihttps://doi.org/10.1592/phco.24.8.736.36064
dc.identifier.citationStroup J, Kane MP, Busch RS, Bakst G, Hamilton RA. The utility of insulin glargine in the treatment of diabetes mellitus. Pharmacotherapy. 2004 Jun;24(6):736-42. doi: 10.1592/phco.24.8.736.36064. PMID: 15222663.
dc.identifier.issn0277-0008
dc.identifier.other15222663
dc.identifier.urihttps://hdl.handle.net/20.500.14303/391
dc.language.isoen
dc.publisherWiley-Blackwell
dc.relation.ispartofPharmacotherapy
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.subjectDiabetes Mellitus, Type 1 / drug therapy
dc.subjectDiabetes Mellitus, Type 2 / drug therapy
dc.subjectDiabetes Mellitus, Type 2 / drug therapy
dc.subjectInsulin / therapeutic use
dc.titleThe utility of insulin glargine in the treatment of diabetes mellitus.
dc.typeArticle
local.departmentprogramDepartment of Pharmacy Practice
Files
Collections
Kane, Michael Publications
Pharmacy Resident Publications